# Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

> **NCT03250676** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 151 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer
- Estrogen-receptor Positive Breast Cancer
- Cancer, Breast
- Breast Cancer Female
- Breast Adenocarcinoma
- Estrogen Receptor Positive Tumor
- ER Positive

## Interventions

- **DRUG:** H3B-6545

## Key facts

- **NCT ID:** NCT03250676
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2023-10-26
- **Final completion:** 2023-10-26
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03250676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03250676, "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03250676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*